Zambon Company SA has extended its presence in respiratory medicines with the acquisition of Breath Therapeutics Holding BV, a clinical-stage company with a product for treating patients with lung transplants who are at risk of dying because of a condition known as bronchiolitis obliterans syndrome (BOS).
